Overview

To Evaluate The Role of Intravitreal Aflibercept Injection (2.0 mg) in the Management of Previously Treated Patients With Exudative AMD

Status:
Completed
Trial end date:
2013-03-01
Target enrollment:
Participant gender:
Summary
This is an open label study to evaluate intravitreally administered 2.0 mg intravitreal aflibercept injection in patients who have been previously treated for AMD and have persistent or recurrent fluid despite monthly intravitreal anti-VEGF therapy.
Phase:
Phase 4
Details
Lead Sponsor:
Vitreous -Retina- Macula Consultants of New York